Introduction
Cytotoxic CD8 + T cells are key players of the immune system that kill virus-infected and cancerous cells by sensing the state of the cellular proteome. A major focus of current studies in the field of cancer immunotherapy is the activation (and reactivation) of tumor-specific T cells, by means of vaccination with tumor-specific antigens, transfer of in vitro-activated tumor infiltrating T cells, and blockade of inhibitory molecules such as CTLA-4 and PD-1 (1-4). Impressive results have been obtained in improvement of patient survival and regressions of cancer lesions, emphasizing the importance of T cells for therapeutic efficacy. Several classes of tumor-specific antigens have been characterized. Highly immunogenic tumor-specific antigens include viral antigens in HPV-induced cervical carcinoma and hepatocellular carcinoma, for which therapeutic peptide vaccination with viral-encoding peptides have been developed and tested with promising results (5-7). Furthermore, neo-antigens arising as a result of DNA mutations in cancer cells offer ideal targets, as T cells have not been centrally tolerized against these antigens. Additionally, some less immunogenic peptides with WT amino acid sequence-such as differentiation antigens, overexpressed antigens, and cancer/testis antigens-are currently under investigation (8) .
Now that T cell-based immunotherapies meet clinical success, the emergence of immune-escape mechanisms of cancers becomes an increasing problem. The selection pressure of immune-mediated therapies on cancer lesions will most likely lead to immune-refractory phenotypes, such as loss of MHC-I antigen presentation. Case studies of immunotherapy in melanoma patients already demonstrated progression of cancer lesions with very low expression of HLA class I, whereas cancer lesions with normal expression of HLA class I in the same patient did regress (9, 10) . Human cancers frequently lose surface expression of HLA class I molecules, and this type of escape constitutes a hurdle for T cell-based therapy. Indeed, these defects correlate with poorer prognosis and metastatic spread, supporting the importance of immune surveillance by tumor-specific CD8 + T cells (10, 11) . HLA class I defects can be caused by structural aberrations or by silencing of gene expression and often involve components of the processing machinery. Interestingly, very similar escape strategies have been described for persistent viruses from the herpes family due to dedicated viral proteins perturbing the function of processing components, such as the peptide transporter associated with antigen processing (TAP) (12) .
We previously identified CD8 + T cells that specifically recognize TAP-deficient tumor cells, which were otherwise resistant to antitumor T cells targeting conventional tumor antigens (13) (14) (15) (16) . The recognition of these MHC-I low tumors depends on TCR/MHC-I interactions and targets a novel class of antigens, called TEIPP (T cell epitopes associated with impaired peptide processing). TEIPP peptides derive from housekeeping proteins that are ubiquitously expressed but only emerge in complex with MHC-I on the cell surface in the absence of the peptide transporter TAP. The prototypic TEIPP antigen is derived from the Trh4 protein, a ceramide synthase spanning the ER membrane. We have demonstrated that processing of the Trh4 epitope is mediated by the signal peptide peptidase enzyme within the lipid bilayer, independently of proteasome and TAP (13) . Although the Trh4 protein is ubiquitously expressed and the MHC-I-restricted Trh4-derived peptide is liberated in all cells, only TAP-deficient cells present the Trh4 peptide/MHC-I at the cell surface, most likely due to peptide competition in the ER (14) . As such, TEIPP peptides are true nonmutated self-antigens.
In the present study, we investigated the generation of the TEIPP T cell repertoire. T cell receptor (TCR) transgenic animals were constructed harboring rearranged receptors recognizing the Trh4/D b complex (named LnB5). We observed efficient selection of this TCR in the thymus, a strong CD8 skewing of the T cells, and high quantities of naïve phenotype in the periphery. The T cells were readily activated by peptide vaccination and killed target cells efficiently. Backcrossing the TCR transgene onto a TAP1-deficient background revealed a strong deletion in the thymus as well as hampered, Helios+ cells in the periphery, underlining the efficient selection of the T cell repertoire in wt mice. Finally, we show that LnB5 tg cells control tumor outgrowth of the TAP2-deficient lymphoma cell line RMA-S. Together, our data demonstrate that TEIPP T cells are not blunted via peripheral or central tolerance and can be exploited for the fight against cancers with defects in the antigen processing machinery. 
Results

TCR determines the selection of TEIPP-specific CD8 + T cells.
We previously isolated a CD8 + T cell clone (LnB5) that specifically recognizes a TEIPP antigen from Trh4, a housekeeping ceramide synthase, presented by the MHC-I molecule D b on TAP-deficient tumor cells. We demonstrated that this Trh4 peptide represents a TEIPP peptide in that it is processed in a proteasome-and TAP-independent manner and is displayed by TAP-deficient cells (13, 14, 16) . To study the generation from the thymus and the behavior in the periphery of TEIPP T cells, we constructed TCR transgenic mice (called hereafter LnB5 tg mice) bearing the rearranged αβ receptors of the Trh4/D b -reactive clone LnB5. First, the TCRαβ were cloned, sequenced (Table 1) and expressed in C57BL/6 splenocytes in order to validate functional production and reactivity of the receptors. After transduction, cell surface expression of the LnB5 TCR was detected by flow cytometry using the Vα3 and Vβ8 antibodies ( Figure 1A ). Since this Vα3-Vβ8 combination is rare in the endogenous population of CD8 T cells of C57BL/6 mice, retroviral introduction of TCRαβ were readily detectable. Stimulation of the transduced cells with the Trh4 peptide resulted in IFNγ production, showing that the cloned TCR conferred recognition of this TEIPP peptide ( Figure 1B ). No IFNγ was detected when TCR transduced cells were stimulated with a control peptide. LnB5 tg mice were then generated using an improved human CD2 promoter and enhancer construct to enforce expression in early thymocytes. In LnB5 tg mice, virtually all (>90%) peripheral CD8 + T cells expressed the transgenic TCR ( Figure 1C) , showing efficient generation of transgenic CD8 + T cells. Hardly any CD4 + T cells were double positive (DP) for the transgenic TCRα and TCRβ, suggesting strong CD8 coreceptor dependence of this TCR. Indeed, a strong skewing towards circulating CD8 + T cells was found, shifting the CD8/CD4 ratio more than 10-fold ( Figure 1 , D and E), similar to what is observed in other transgenic mice models that express MHC-I-restricted TCR (17, 18) . Importantly, CD8 + T cells clearly displayed a naïve phenotype, comparable to CD8 + T cells from the endogenous repertoire of wt C57BL/6 mice ( Figure 1F ). Furthermore, no expression was detected on naïve LnB5 cells of several analyzed NK receptors (NK1.1, Ly49H, NKG2A, CD94, CD49b and NKG2D), implying that the generation of TEIPP T cells was determined by the TCR and did not depend on these NK receptors, which are closely associated with immune recognition of MHC-I low target cells ( Figure 1G ). In conclusion, the LnB5 TCR is sufficient to confer TEIPP reactivity and governs the generation of TEIPP CD8 + T cells.
Thymus education on TAP1 -/background largely deletes LnB5 T cells and severely hampers their function.
The skewing toward the CD8 + T cell lineage observed in LnB5 tg mice suggested a normal thymic selection in these mice, although we previously demonstrated that epithelial cells in the thymus express the Trh4 gene and also present peptide/D b complexes when deficient for TAP function (14) . As expected, a clear CD8 + single positive (SP) population was observed in thymi of LnB5 tg mice on a C57BL/6 background (LnB5wt) and a reduced DP population, most likely due to the efficient selection of CD8 + T cells (Figure 2A ). To study the thymic selection on an antigen-positive background, LnB5tg mice were crossed on a TAP1-deficient background (LnB5TAP -/-). Thymi of LnB5TAP1 -/mice lacked a dis tinct mature CD8 + SP population; instead, a small subset of thymocytes with intermediate CD8 and low CD4 expression was found ( Figure 2A ). The DP population was severely reduced, suggesting a fast deletion of TCRαβ+ thymocytes. Moreover, the overall cellularity of the thymus was dramatically decreased ( Figure 2B ), again suggesting negative selection. When absolute counts of thymocytes were plotted for each developmental stage (double negative [DN], DP, CD4 + SP and CD8 + SP), clear differences were observed between LnB5TAP1 -/and nontransgenic TAP1 -/mice, indicating that the aberrations were not the result of a lack of stimulation due to low MHC-I levels but were related to Trh4 antigen presentation ( Figure 2C ). CD8 + SP cells in LnB5wt and LnB5TAP -/mice had comparable levels of the TCRβ chain (Vβ8), which was driven by the heterologous hCD2 promoter ( Figure 2D ). However, CD8 + SP cells in LnB5TAP -/mice had reduced CD8 and Trh4/D b -tetramer staining levels, indicative of reduced TCR avidity (19) . Additionally, cells in these mice had an increased expression of the transcription factor Helios, a member of the Ikaros family of transcription factors, associated with self-reactive T cells (20, 21) . The increased Helios expression could not be attributed to the TAP1 -/background per se, as no difference in Helios expression was observed in CD8 + SP cells in normal C57BL/6 or TAP1 -/mice (Supplemental Figure 1A ). The major deletions in thymic cellularity, especially of the DP and CD8 + SP and the reduced TCR avidity of the latter populations, suggested severe negative deletion in LnB5tg mice on a TAP -/background.
Next, we analyzed the peripheral phenotype and function of these TEIPP T cells. The strong skewing towards the CD8 + T cell lineage, as observed in the periphery of mice on the wt background, was completely lost in LnB5TAP -/mice ( Figure 2E and Supplemental Figure 1B) . Very low frequencies of CD8 + T cells, but also CD4 + T cells were observed in LnB5TAP1 -/mice and CD8/CD4 ratios of LnB5TAP1 -/mice approached those of C57BL/6 mice ( Figure 2E ). All the residual CD8 + T cells in the blood of LnB5TAP1 -/mice demonstrated an antigen-experienced phenotype, as witnessed by expression of Ly6C and CD122 (Supplemental figure 1C ). In addition, the peripheral CD8 + T cells expressed high levels of the transcription factor Helios (Supplemental figure 1D ). The Helios + CD8 + T cells in LnB5TAP -/mice did not express FoxP3 (data not shown), but we speculate that Helios expression is a result of the high activation status of LnB5 T cells in this Trh4/D b presenting environment. In concordance with cells in the thymus, peripheral CD8 + T cells displayed decreased levels of CD8α and Trh4/D b tetramers (Supplemental Figure 1D ).
To examine the functionality of the CD8 + T cells that were educated on TAP1 -/background, they were isolated from spleen and lymph nodes and used in an in vitro proliferation assay with or without Trh4 peptide stimulation. All CD8 + T cells from LnB5wt mice underwent proliferation upon Trh4 peptide encounter and produced IFNγ (Figure 2 , F and G). In contrast, a very small percentage of CD8 + T cells from LnB5TAP -/mice proliferated when stimulated with the cognate peptide in vitro, and much lower quantities of IFNγ were produced. From these data, we concluded that the hampered function of CD8 + T cells raised in TAP1 -/mice was related to thymic selection on an antigen-positive background. Importantly, all these observed characteristics of negative selection of LnB5 T cells on TAP1 -/background corroborated our conclusion that the TEIPP T cell repertoire is not hampered on normal wt background. 
The preferential recognition of TAP-deficient target cells is determined by TEIPP TCR.
We next explored the functional properties of TEIPP-specific LnB5 tg T cells ex vivo in more detail. To this end, naïve CD8 + T cells were purified from spleen and lymph nodes of LnB5 tg, labeled with CFSE, and cultured in the presence of various stimuli. After 3 days, proliferation and cytokine production were analyzed ( Figure 3, A and B ). Upon stimulation with agonistic αCD3/αCD28 antibodies, TEIPP T cells strongly proliferated to a comparable extent as CD8 + T cells from wt C57BL/6 mice ( Figure 3A) . In addition, cells produced both IFNγ and TNFα at high levels ( Figure 3B ). Stimulation with cognate Trh4 peptide also resulted in proliferation and IFNγ production, whereas this was not detected when the T cells were incubated with a control peptide. Production of TNFα was lower, but clearly detectable. Next, the IFNγ response of in vitro primed LnB5 tg T cells was measured to a panel of natural targets and compared with the original TEIPP T cell clone LnB5 ( Figure 3C ). The TAP2-deficient lymphoma RMA-S, as well as DCs from TAP1 -/mice, stimulated LnB5 tg T cells much stronger than their TAP-proficient counterparts, similar to the original T cell clone. Together, our data reveal that both TEIPP reactivity and TEIPP specificity are determined by the TCR.
TEIPP T cells remain ignorant after transfer in wt mice, even in inflammatory conditions
The observations on the in vitro responses of LnB5 tg T cells incited us to investigate the in vivo behavior of these TEIPP CD8 + T cells in settings of display of the Trh4 self-antigen. Naïve CFSE-labeled LnB5 tg T cells were transferred into wt C57BL/6 mice and TAP1 -/mice, both expressing comparable levels of the Trh4 gene in their organs ( Figure  4A ) (14) . Three days after T cell transfer, the LnB5 T cells had undergone several cycles of proliferation in TAP1 -/mice, but the cells in the wt mice did not proliferate ( Figure  4B ). Interestingly, the proliferating T cells in TAP-deficient mice did not accumulate and did not display CD62L downregulation, strongly suggesting that they underwent abortive proliferation, a form of T cell activation leading to functional tolerance previously described to occur due to the absence of inflammatory signals (22, 23) . To examine whether the lack of activation and accumulation of LnB5 cells in TAP1 -/mice was due to this process, mice were given agonistic αCD40 antibody, which potently activates antigen presenting cells (24) . In αCD40-treated mice, LnB5 tg T cells indeed underwent a larger amount of division cycles, strongly accumulated in the hosts and downregulated CD62L (Figure 4, B and C) . Thus, the addition of agonistic αCD40 antibody led to proper T cell activation. Importantly, T cells in wt animals did not show any sign of antigen stimulation, even though the Trh4 protein is present in these animals and strong inflammatory signals were provided (Figure 3 , B and C). To exclude that TEIPP T cells proliferated in TAP1 -/mice as a result of homeostatic proliferation, we transferred two control TCR tg T cells, one with foreign-and one with self-specificity (OVA and gp100, respectively). No proliferation and no activation of the OVA-specific OT-I and the gp100-specific pmel T cells was observed when transferred in TAP1 -/mice (Figure 4 , D and E). This indicates that proliferation of LnB5 tg T cells in TAP1 -/mice was antigen-driven and not the result of homeostatic proliferation. Importantly, these data also demonstrate that TEIPP T cells remain ignorant in wt mice, even in the presence of inflammatory signals. 
Efficient cross-priming of TEIPP T cells by vaccination with a synthetic long peptide.
As TAP-deficient antigen-presenting cells efficiently primed LnB5 tg T cells in TAP1 -/mice and endogenous Trh4 proteins in wt mice apparently failed to cross-prime TEIPP T cells, we examined the capability of vaccination approaches to induce TEIPP T cell responses in a wt background in which all antigen-presenting cells are TAP-proficient. First, we investigated whether TAP-proficient dendritic cells (DCs) processed and presented longer versions of synthetic peptides comprising TEIPP epitopes. DCs were incubated for 4 5 hours with HPLC-purified 21-mer long Trh4 peptide and after extensive washing, offered to LnB5 T cells. These peptide-loaded DCs were surprisingly efficient in stimulating the T cells, indicating that TAP-proficient DCs are capable of cross-presenting exogenously loaded long TEIPP peptides ( Figure 5A ). Next, wt mice were vaccinated with the purified long Trh4 peptide and the response of transferred naïve LnB5 tg T cells was measured over time ( Figure 5B ). After the second vaccination, an extensive expansion of the congenically marked T cells was observed, accompanied by proper activation ( Figure 5C ) and IFNγ production ( Figure 5D ). The strength and magnitude of the response were rather similar to those achieved with vaccination using the minimal short peptide, demonstrating that TAP-proficient host DCs in wt mice are impeccably capable to cross-prime TEIPP T cells.
To measure killing capacities of activated TEIPP T cells, an in vivo cytotoxicity assay was performed. Vaccinated animals were challenged with differentially CFSE labeled splenocytes pulsed with either short Trh4 peptide or control peptide. More than 80% of the Trh4-pulsed target cells were killed in vaccinated mice ( Figure 5 , E and F). Of note, vaccination did not induce a cytolytic T cell response from the endogenous CD8 T cell repertoire, since transfer of naïve LnB5 tg T cells was necessary to observe killing. The precursor frequencies of Trh4/D b -reactive T cells is most likely too low for this type of assay, as previous findings already revealed that this epitope is subdominant in this model (25) . Next, splenocytes from C57BL/6 and TAP1 -/mice were used as target populations (Figure 4, G and H) . Approximately 30% of TAP-deficient splenocytes were selectively killed. These experiments were performed in the absence of NK cells to prevent NK-mediated killing of TAP-deficient and MHC-I low targets. Taken together, we demonstrate that TEIPP T cells can be efficiently primed in vivo by cross-presentation, resulting in properly activated CD8 + TEIPP T cells with potent killing capacities. 
Effective tumor control delay by LnB5 tg cells.
The efficient killing of surrogate target cells by LnB5 tg cells after peptide vaccination prompted us to examine the control of TAP-deficient tumor cells. To this end, we used the highly aggressive, TAP2-deficient lymphoma RMA-S. These tumors display a minimal level of MHC-I at their cell surface and are refractory to conventional antitumor cytotoxic T lymphocyte (CTL). Mice were inoculated with tumor cells, and when a palpable tumor was present, mice were treated by adoptive transfer of LnB5 tg cells and peptide vaccination according to the protocol used before ( Figure 6A ). Without treatment, RMA-S tumors grew out rapidly, and mice had to be sacrificed within 20 days after tumor challenge ( Figure 6B and C). Addition of LnB5 tg cells did not result in delay in tumor outgrowth, consistent with the fact that that peptide vaccination is needed to activate LnB5 tg T cells in wt hosts. T cell transfer in combination with peptide vaccination resulted in a significant delay of tumor outgrowth and survival of a quarter of the animals ( Figure 6 , B and C, and Supplemental Figure 2A ). Peptide vaccination alone resulted in a modestly reduced tumor outgrowth, most likely due to CpG-activated NK cells. In blood of vaccinated mice, expansion and activation of LnB5 tg T cells was observed ( Figure 6 , D and E). We were interested in a possible contribution of NK cells in our model, since the RMA-S tumor is a well-known target for killing by these innate cells (26, 27) . To this end, NK cells were depleted during the RMA-S tumor-treatment experiment, starting one day before T cell transfer. At day 15 after tumor challenge, mice that received LnB5 tg T cells and subsequent vaccination had a significantly reduced tumor size compared with untreated mice even in the absence of NK cells ( Figure 6F ). The observed reduction in tumor size was mediated by vaccination-induced stimulation of the transferred LnB5 T cells. Interestingly, TEIPP T cells and NK cells appeared to collaborate for the long-term control of RMA-S tumors (Supplemental Figure 2B) . Together, these results show that TEIPP T cells can delay and control tumor outgrowth of tumors with antigen-processing defects that are otherwise resistant to antitumor CTL. 
Discussion
Here we report on the thymic selection and functional behavior of T cells specific for self-antigens, called TEIPP, that emerge on cells with defects in the antigen-processing machinery. Our research on TEIPP antigens has thus far mainly focused on the antigens and their intracellular processing and presentation pathway (13, 14) . There we found that TEIPPs are derived from ubiquitously expressed housekeeping proteins, are presented as short peptides in MHC-I molecules (classical and nonclassical), and are processed via alternative routes, independent of the peptide transporter TAP (28) . Although they are germline encoded, nonmutated self-antigens, TEIPP antigens are true neoantigens because they are selectively presented on the surface of cells with impaired TAP function. Therefore, TEIPPs emerge de novo in the MHC-I peptide repertoire and possess immunogenicity due to their ''hidden'' feature under normal conditions. In our current work, we demonstrated that the prototypic TEIPP antigen from Trh4 is not presented on tissues of the body, even in inflammatory conditions like systemic triggering of CD40. Even in these conditions of sterile inflammation, TEIPP T cells did not undergo antigendriven activation. Systemic triggering of CD40 receptors have been shown to induce massive activation of B cells, macrophages, and DCs and, moreover, lead to systemic release of immunostimulatory cytokines (24) . In contrast, deficiency in the peptide transporter TAP readily induced presentation of the antigen.
Due to the ''selfness'' of this category of cancer antigens, the risks of autoreactivity and also tolerance induction are at hand and needed careful investigation. Here, we studied some of these issues using LnB5 tg mice. We found that TEIPP-specific CD8 + T cells are efficiently selected in the thymus and display a naïve phenotype in the periphery. No signs of central thymic tolerance were observed. We conclude that developing TEIPP T cells do not encounter their cognate antigen in the thymus and are thus released into the periphery as a noncurtailed repertoire. In parallel, TEIPP T cells also appeared to remain ignorant in the periphery. Antigenic stimulation with peptide vaccines or Trh4 antigen-presenting cells (APCs) in TAP1 -/mice did lead to strong activation of TEIPP T cells. Together, these results represent a broad therapeutic window for TEIPP antigens and the availability of an unspoiled, ignorant T cell repertoire that is a strong asset for exploitation of TEIPP antigens in immunotherapy of cancer. Auto-pathology to healthy tissues is not anticipated for TEIPP-targeted immunotherapy, in contrast to the exploitation of other self-antigens in immunotherapeutic approaches for cancer treatment. Socalled cancer/testis antigens and cancer differentiation antigens have shown that, although a safe therapeutic window was anticipated, T cell-mediated auto-pathology constitutes a serious problem. Effective antitumor T cell responses against overexpressed differentiation antigens, like tyrosinase and gp100, have been shown to cause autopathology to the melanocytes in the conjunctiva layer of the eye and in the cochlea of the inner ear, leading to visual and hearing degeneration (29, 30) . Obviously, these on-target adverse effects are more drastic than skin depigmentation and are clearly dose-limiting and preclude further exploitation. Similarly, the unexpected expression of MAGE-A12 protein in the brain caused unacceptable neurotoxicity in a TCR gene therapy trial, although MAGE is the classical example of a cancer/testis antigen (31) . Our data indicate that the category of TEIPP cancer antigens, although being self-antigens, can best be classified in the group of viral non-self-antigens in that they are clearly foreign for the T cell immune system.
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TEIPP T cells were found to be activated by vaccination with synthetic long peptides composing the minimal CD8 T cell epitope. From these results, we deduced that TAP-proficient host APCs were able to internalize these long peptides, digest, and cross-present them in MHC-I molecules in the face of the full competing peptide repertoire; thus, immunotherapy with TEIPP antigens can be exploited using this platform. We currently investigate how these host APCs manage to achieve this and which antigen processing pathway is responsible for this function.
Together, the observed characteristics of TEIPP T cells all point at an optimal window of opportunity for exploitation of these T cells for immunotherapy of cancers with antigen-processing defects. Deficiencies in components of the antigen-processing machinery in tumors have been correlated with poor prognosis and metastasi,s and the urge to find therapies for these immune-escaped variants becomes urgent now that immunotherapy reaches clinical success (10, (32) (33) (34) (35) (36) . The delayed tumor outgrowth of the aggressive MHC-I low lymphoma RMA-S tumor after TEIPP T cell transfer and vaccination nicely illustrated the anti-tumor potency of this CD8 + T cell subset and provides us with tools to counteract tumors that have escaped from conventional immunotherapies. In conclusion, we show that TEIPP T cells are efficiently selected in the thymus and are not blunted by central or peripheral tolerance mechanisms, can readily be activated by vaccination, and can delay tumor outgrowth of antigen-processing deficient tumor cells. This CD8 + T cell subset might complement conventional therapies to prevent outgrowth of immune-escaped cancer cells.
Materials and methods
Cell lines and mice
The tumor cell lines RMA, RMA-S (TAP2 deficient), RMA-S.B7.1 (RMA-S transfected with mouse CD80 gene) and DC line D1 have been described before (13, 16) . C57BL/6 and TAP1 -/-DCs were generated from BM from C57BL/6 and TAP1 -/mice, respectively and were cultured for 1 week in the presence of IL-4 and GM-CSF. The generation and culture of TEIPP T cell clone LnB5, with specificity for the Trh4-derived peptide MCL-RMTAVM in the context of H-2D b has been previously described (13) . All cells were cultured in complete IMDM medium (Invitrogen) containing 8% heat-inactivated FCS (Gibco), 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine (Invitrogen) at 37° C in humidified air with 5% CO 2 . C57BL/6 mice were purchased from Charles River Laboratories. The TAP1 -/mice (catalog 00294) and the OT-I tg mice (catalog 003831), containing the OVA 257-264 /K b -restricted T cell receptors were derived from Jackson Laboratory. The pmel TCR transgenic mice, containing the gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] / D b -specific T cell receptors, were a gift from N.P. Restifo (National Cancer Institute, Bethesda, Maryland, USA). Mice were housed in individually ventilated cages and used at 6-12 weeks of age.
Generation of LnB5 T cell receptor transgenic mice
The LnB5 TCR transgenic mouse strain was generated by transgenesis of the TCRα and TCRβ genes of the LnB5 T cell clone, specific for the Trh4/D b complex. Cloning and sequencing of the TCR chains identified the α chain as composed by TRAV9N-3*01 and TRAJ15*01 and the βchain composed by V13-2*01, D1*01, and J1-4*02, according to the ImMunoGeneTics nomenclature (Table 1 and www.imgt.org). The TCRα and TCRβ chains were separately cloned into pCRII-TOPO plasmid vectors (Invitrogen) using reverse transcription PCR (RT-PCR). Validation of correct TCR cloning was performed by retroviral transduction of the TCR in C57BL/6 splenocytes using pMX vectors (Ton Schumacher, NKI). Next, the 2 chains were separately cloned into VA-hCD2 vectors (37) , the inserts of which were subsequently injected in C57BL/6 oocytes to produce transgenic mice. DNA from tails of founder mice was analyzed by PCR for presence of the constructs, using the forward primer in the CD2 cassette: 5'-GGTGTGGACTCCACC AGTCTCACTTC-3' and the reverse primer in the TCRα: 5'-TAACTGGTACACAGCAGG-3' or TCRβ region: 5'-CAAACAAGGAGAGACCTTG-3' (Invitrogen). Blood samples of transgenic offspring mice were screened for presence of TCR transgenic T cells using specific antibodies to TCR Vα3 (clone RR3-16, BioLegend) and TCR Vβ8 (clone KJ-16-133.18, BioLegend). 
Adoptive cell transfer, vaccination, and in vivo cytotoxicity assay.
For T cell transfer assays, single cell suspensions were made by mechanical disruption of spleen and lymph nodes of LnB5 tg mice. Cells were passed through nylon wool to enrich for T cells, and 3x10 6 CD8 + T cells were injected in 200 µl PBS i.v. in recipient mice. Peptide vaccination was performed at day 1 and day 8 after T cell transfer with 50 μg of the proline-modified 9-mer Trh4 peptide (MCPRMTAVM) (38, 39) 
In vitro stimulations and cross-presentation experiments.
For in vitro T cell assays with naïve transgenic LnB5 T cells, spleen and lymph nodes were isolated, and CD8 + T cells were enriched using nylon wool, and purified using the CD8 + enrichment kit (BD Biosciences) and labeled with 5 μM CFSE. A total of 100,000 cells were put in a 96-well plate with various stimuli in the presence of 10CU IL-2/ml. For αCD3/αCD28 stimulation, wells of a 96-well plate were coated overnight with 0.5 µg/ml αCD3 (145-2C11, BD) in 100µl PBS. The next day, coated wells were washed with medium, and cells were added with 2 µg/ml αCD28 (37.51, Biolegend). For peptide stimulation, 1 µg/ml peptide was added to the wells and at day 1 and day 2 after start of the experiment, 1 µl of 1 µg/ml peptide solution was added to the corresponding well. Three days after start of the culture, cells were analyzed by flow cytometry and supernatants were analyzed for cytokine release measured by IFNγ ELISA as described previously or by Cytokine Bead Array assay (BD Bioscience). For cross-presentation experiments, DC line D1 was loaded for 5 hours with 21mer long Trh4 peptide (HPLC purified to >95%). Cells were thereafter washed extensively. D1 cells (50.000) were co-cultured with 50.000 LnB5 T cells in the presence of GolgiPlug (BD). The following day, intracellular cytokine was performed as described previously.
Tumor experiments
C57BL/6 mice were inoculated with 2x10 6 RMA-S cells in 200 µl 0.1% BSA/PBS s.c. in the left flank. Four days later, 3x10 6 nylonwool-purified splenocytes from LnB5 tg mice were injected i.v. At day 5 and 12, mice were vaccinated with 50 µg of the (short) proline-modified Trh4 peptide with 20µg CpG in 200 µl PBS s.c. in the opposite flank. Additionally, mice received 100.000 U IL-2 at days 12 and 13. Tumor sizes were measured using a caliper, and mice were sacrificed when the tumor size reached 2000mm 3 . In the 4 NK cell-depletion experiment, NK cells were depleted using 100 µg PK136 depleting antibody, starting the day before T cell transfer. Depletion was maintained every 3-4 days.
Statistics
Statistical analyses were done in GraphPad Prism, version 6.0. In tumor experiments, Kaplan Meier survival curves of mice was analyzed using log-rank assay. Additional statistical methods are described in the legend. P values < 0.05 were considered statistically significant.
Study approval
All animal experiments were approved by the ethics committee of the LUMC.
Supplemental figure 2: Control of RMA-S tumors by TEIPP T cells.
(A) At day 4 after RMA-S tumor challenge, LnB5 tg T cells were transferred and were vaccinated according to the vaccination scheme described before. Mice were vaccinated with the long helper peptide from the Env-peptide from the MulV-virus(40), which induced the RMA tumor from which the RMA-S is derived, with or without the minimal Trh4 peptide. Data from one experiment, with three mice per group. (B) One day before T cell transfer, NK cells were depleted, and mice were vaccinated with the Trh4 peptide in combination with CpG as described before. Data from one experiment, with eight mice per group. 
